Prognostic Value of FDG PET Metabolic Tumor Volume in Human Papillomavirus-positive Stage III and IV Oropharyngeal Squamous Cell Carcinoma

Overview

Journal AJR Am J Roentgenol

Specialties Oncology
Radiology

Date 2014 Sep 24

PMID 25247958

Citations 22

Authors

Krishna C Alluri

Abdel K Tahari

Richard L Wahl

Wayne Koch

Christine H Chung

Rathan M Subramaniam

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to establish the prognostic utility in human papillomavirus (HPV)-positive stage III and IV oropharyngeal squamous cell carcinoma (SCC) of the (18)F-FDG parameters maximal, mean, and peak standardized uptake value (SUVmax, SUVmean, and SUVpeak, respectively); metabolic tumor volume (MTV); and total lesion glycolysis (TLG).

Materials And Methods: We included 70 patients in the present study who had a biopsy-proven HPV-positive (by in situ hybridization) stage III and IV oropharyngeal SCC and had a baseline PET/CT examination at our institution. Outcome endpoint was event-free survival (EFS), which included recurrence-free and overall survival. Cox proportional hazards multivariate regression analyses were performed. Survival analysis was performed using Kaplan-Meier survival curves.

Results: In Cox regression proportional hazard univariate analysis, total MTV (hazard ratio [HR], 1.02; p = 0.008), primary-tumor MTV (HR, 1.02; p = 0.024), neck nodal MTV (HR, 1.03; p = 0.006), neck nodal TLG (HR, 1.01; p = 0.006), and neck node status (HR, 4.45; p = 0.03) showed a statistically significant association with EFS. There was no statistically significant association of EFS with SUVmax, SUVmean, SUVpeak, and primary-tumor or overall TLG. In Cox regression proportional hazard multivariate model I, total MTV remained an independent prognostic marker for EFS when adjusted for every other variable individually in the model; in model II, primary-tumor MTV, neck node status, and SUVpeak are independent prognostic markers for EFS. The Kaplan-Meier survival curves using optimum cut point of 41 mL of total MTV were not significant (p = 0.09).

Conclusion: Total MTV and primary-tumor MTV are associated with survival outcomes in patients with HPV-positive stage III and IV oropharyngeal SCC.

Citing Articles

Utility and limitations of metabolic parameters in head and neck cancer: finding a practical segmentation method.

Rijo-Cedeno J, Mucientes J, Villarreal I, Royuela A, Garcia Vicente P, Garcia-Berrocal J Eur Arch Otorhinolaryngol. 2022; 279(9):4577-4586.

PMID: 35499622 PMC: 9363397. DOI: 10.1007/s00405-022-07401-y.

Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology.

Salzillo T, Taku N, Wahid K, McDonald B, Wang J, van Dijk L Semin Radiat Oncol. 2021; 31(4):371-388.

PMID: 34455992 PMC: 9273339. DOI: 10.1016/j.semradonc.2021.05.001.

Artificial Intelligence and Radiomics in Head and Neck Cancer Care: Opportunities, Mechanics, and Challenges.

van Dijk L, Fuller C Am Soc Clin Oncol Educ Book. 2021; 41:1-11.

PMID: 33929877 PMC: 8218312. DOI: 10.1200/EDBK_320951.

Analysis of PET parameters as prognosticators of survival and tumor extent in Oropharyngeal Cancer treated with surgery and postoperative radiotherapy.

Choi K, Song J, Park E, Hong J, Yoo I, Lee Y BMC Cancer. 2021; 21(1):317.

PMID: 33765966 PMC: 7992344. DOI: 10.1186/s12885-021-08035-9.

Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model.

Spanier G, Weidt D, Hellwig D, Meier J, Reichert T, Grosse J Oncotarget. 2021; 12(1):37-48.

PMID: 33456712 PMC: 7800778. DOI: 10.18632/oncotarget.27857.

References

Rischin D, Young R, Fisher R, Fox S, Le Q, Peters L . Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 28(27):4142-8. PMC: 2953971. DOI: 10.1200/JCO.2010.29.2904. View

Tang C, Murphy J, Khong B, La T, Kong C, Fischbein N . Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012; 83(5):1514-20. PMC: 3337958. DOI: 10.1016/j.ijrobp.2011.10.023. View

Pannone G, Rodolico V, Santoro A, Lo Muzio L, Franco R, Botti G . Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer. 2012; 7:4. PMC: 3313884. DOI: 10.1186/1750-9378-7-4. View

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

OSullivan B, Huang S, Perez-Ordonez B, Massey C, Siu L, Weinreb I . Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol. 2012; 103(1):49-56. DOI: 10.1016/j.radonc.2012.02.009. View

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T . Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2003; 22(1):69-76. DOI: 10.1200/JCO.2004.08.021. View

La T, Filion E, Turnbull B, Chu J, Lee P, Nguyen K . Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009; 74(5):1335-41. PMC: 2752334. DOI: 10.1016/j.ijrobp.2008.10.060. View

Fakhry C, Westra W, Li S, Cmelak A, Ridge J, Pinto H . Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100(4):261-9. DOI: 10.1093/jnci/djn011. View

10.

Xie P, Yue J, Zhao H, Sun X, Kong L, Fu Z . Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2009; 136(6):883-9. DOI: 10.1007/s00432-009-0729-7. View

11.

Werner-Wasik M, Nelson A, Choi W, Arai Y, Faulhaber P, Kang P . What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2011; 82(3):1164-71. PMC: 3877699. DOI: 10.1016/j.ijrobp.2010.12.055. View

12.

Torizuka T, Tanizaki Y, Kanno T, Futatsubashi M, Naitou K, Ueda Y . Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol. 2009; 192(4):W156-60. DOI: 10.2214/AJR.08.1429. View

13.

Quon H, Richmon J . Treatment deintensification strategies for HPV-associated head and neck carcinomas. Otolaryngol Clin North Am. 2012; 45(4):845-61. DOI: 10.1016/j.otc.2012.04.007. View

14.

Pignon J, Le Maitre A, Maillard E, Bourhis J . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1):4-14. DOI: 10.1016/j.radonc.2009.04.014. View

15.

Allal A, Slosman D, Kebdani T, Allaoua M, Lehmann W, Dulguerov P . Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004; 59(5):1295-300. DOI: 10.1016/j.ijrobp.2003.12.039. View

16.

Romesser P, Qureshi M, Shah B, Chatburn L, Jalisi S, Devaiah A . Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012; 26(7):527-34. PMC: 4483182. DOI: 10.1007/s12149-012-0604-5. View

17.

Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P . Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999; 91(24):2081-6. DOI: 10.1093/jnci/91.24.2081. View

18.

Thomas J, Primeaux T . Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma?. Ann Diagn Pathol. 2011; 16(2):91-9. DOI: 10.1016/j.anndiagpath.2011.09.002. View

19.

Dibble E, Alvarez A, Truong M, Mercier G, Cook E, Subramaniam R . 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012; 53(5):709-15. DOI: 10.2967/jnumed.111.099531. View

20.

Liao C, Chang J, Wang H, Ng S, Hsueh C, Lee L . Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 2008; 73(3):764-71. DOI: 10.1016/j.ijrobp.2008.05.004. View